Your genetic results do not predict the exact time of day semaglutide will work best for you, nor do they override the clinical evidence supporting weekly consistency
However, it is noteworthy that a similar proportion of patients in both groups achieved a clinically significant total body weight loss of 5% or more and 10% or more at 12 months, which indicates the efficacy of this medication for both groups of patients. Researchers performed a retrospective cohort study with data from 305 adults with overweight or obesity who received once-weekly subcutaneous semaglutide (Wegovy, Novo Nordisk) at a Mayo Clinic center from 2021 to Jan
Significant complications are uncommon and, in the rare event they occur, are expertly managed
In the non-T2D cohort, participants were matched and compared after six months of treatment with either tirzepatide (cohort 1a, n = 6923) or semaglutide (cohort 2a, 6923), with a follow-up of 12 months to assess the incidence of T2D and changes in glycated hemoglobin (HbA1c), body weight, hypoglycemia, and acute pancreatitis
)
